“The additional $1.2 billion that we've identified. Probably modest delivery of that in 2025, most of that in 2026 and 2027, but maybe a little bit.”

In context

“can come out in 2025? And how should we think about the step up of cost for the rest of the year following what seems to be you guys exceeding savings targets, but also reiterating a guide. And then on BD, you've mentioned external opportunities. How much is that macro environment impacting your decision in the timing of BD given the volatility and unknowns? And then on the other side of the table, do you think sellers are hesitating given valuations are meaningfully lower than the start of the year? Thanks. Albert Bourla: Okay. Dave, why don't you take the guidance? And then, Andrew, you can speak to the BD a little bit and I will also comment. Dave Denton: Yeah. On the cost side, keep in mind that we're focused on taking $4.5 billion out by the end of this year. Well on track with that. The additional $1.2 billion that we've identified. Probably modest delivery of that in 2025, most of that in 2026 and 2027, but maybe a little bit. I think from an R&D perspective, the $500 million that we're saving in improving productivity in R&D, largely, that will happen this year. To be reinvested in R&D late this year or maybe even bleed into next year to some degree. Albert Bourla: Thank you. And on BD, Andrew, valuations are low. Uncertainty is high. So how do you see things? Andrew Baum: Yeah. I mean, I think as you might imagine, we're very awake to the external environment, but we're comfortable with the $10 to $15 billion budget that Dave effectively forecasted or gave beginning of this year. In terms of the question of have sellers adjusted to the new valuation the market's applying. I think it depends. I think generally it takes some time in some categories where there is increasing therapeutic density because there's a”